Drug · DIN 00868973
SUPRAX
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since May 5, 2006; first marketed December 31, 1990.
- Drug Identification Number (DIN)
- 00868973
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Cefixime J01DD08
- Class
- Human
- Record last updated
- June 12, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| CEFIXIME | 200 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 4, 2006: NOC 7927New Drug Submission (NDS) · Manufacturer name change
- December 24, 2004: NOC 6014New Drug Submission (NDS) · Manufacturer name change
Other DINs named SUPRAX
- DIN 00868965 · Marketed
- DIN 00868981 · Marketed
- DIN 02195984 · Cancelled Post Market
- DIN 02195992 · Cancelled Post Market